

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6015031

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
LEAH BLASIAK	01/16/2020
WILLIAM NATHAN CUDE	01/16/2020
YAOWEI KANG	01/17/2020
KATE BRANDON SUTTON	01/07/2020
TIMOTHY LIBURN	01/17/2020
JONATHAN PHAM	01/06/2020
RECEIVING PARTY DATA	
Name:	NOVOZYMES BIOAG A/S
Street Address:	KROGSHOEJVEJ 36
City:	BAGSVAERD
State/Country:	DENMARK
Postal Code:	DK-2880
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	US1812152
CORRESPONDENCE DATA	
Fax Number:	(919)405-1885
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	919-494-3000
Email:	DOCKETING@novozymes.com
Correspondent Name:	NOVOZYMES NORTH AMERICA, INC. US PATENT
Address Line 1:	77 PERRYS CHAPEL CHURCH ROAD
Address Line 2:	PO BOX 576
Address Line 4:	FRANKLINTON, NORTH CAROLINA 27525-0576
ATTORNEY DOCKET NUMBER:	14442-US-PCT
NAME OF SUBMITTER:	ADAM RUCKER
SIGNATURE:	/Adam L. Rucker, Reg. No. 65933/
DATE SIGNED:	03/16/2020
This document serves as an Oath/Declaration (37 CFR 1.63).	

PATENT

Total Attachments: 7

source=Pham_DecAssign#page1.tif

source=Pham_DecAssign#page2.tif

source=DecAssign#page1.tif

source=DecAssign#page2.tif

source=Substitute_Oath_Kang#page1.tif

source=Substitute_Oath_Kang#page2.tif

source=Substitute_Oath_Kang#page3.tif

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COMBINED DECLARATION (37 CFR 1.63) AND ASSIGNMENT FOR UTILITY OR DESIGN
APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

DECLARATION

As the below named inventor, I declare that:

This declaration is directed to the invention entitled

BACILLUS ISOLATES AND USES THEREOF

for which a PCT application designating the United States, was filed on **January 3, 2018**,
application number **PCT/US2018/012152**.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the
application.

I hereby acknowledge that any willful false statement made in this declaration is punishable
under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT

WHEREAS:

Novozymes BioAg A/S of Krogshoejvej 36, DK-2880 Bagsvaerd, Denmark (hereinafter
ASSIGNEE), is desirous of acquiring the entire right, title and interest in the same;

NOW, THEREFORE, in consideration of the sum of one dollar (\$1), the receipt of which is
acknowledged, and other good and valuable consideration, I do sell, assign and transfer to
ASSIGNEE the full and exclusive right to the said invention in the United States and in all
foreign countries and the entire right, title and interest in and to any and all patents or similar
legal protection which may granted therefor in the United States and in all foreign countries from
said application or any continuation, division, renewal, extension, substitute or reissue thereof or
any legal equivalent thereof in a foreign country. I hereby authorize and request the
Commissioner of Patents and Trademarks and any official of any foreign country whose duty it
is to issue patents on applications as aforesaid, to issue said United States and foreign patents
to ASSIGNEE, of the entire right, title and interest in and to same, for his sole use and behoof;
and for the use and behoof of his legal representatives, to the full end of the term for which said
patents may be granted, as fully and entirely as the same would have been held by us had this
assignment and sale not been made.


SOLE OR FIRST INVENTOR	
Name	Leah Blasiak
Inventor's Signature	
Date	

SECOND INVENTOR	
Name	William Nathan Cude
Inventor's Signature	
Date	

THIRD INVENTOR	
Name	Yaowei Kang
Inventor's Signature	
Date	

FOURTH INVENTOR	
Name	Kate Brandon Sutton
Inventor's Signature	
Date	

FIFTH INVENTOR	
Name	Timothy Liburn
Inventor's Signature	
Date	

SIXTH INVENTOR	
Name	Jonathan Pham
Inventor's Signature	
Date	1/6/2020

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**COMBINED DECLARATION (37 CFR 1.63) AND ASSIGNMENT FOR UTILITY OR DESIGN
APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

DECLARATION

As the below named inventor, I declare that:

This declaration is directed to the invention entitled

BACILLUS ISOLATES AND USES THEREOF

for which a PCT application designating the United States, was filed on **January 3, 2018**, application number **PCT/US2018/012152**.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.


ASSIGNMENT

WHEREAS:


Novozymes BioAg A/S of Krogshoejvej 36, DK-2880 Bagsvaerd, Denmark (hereinafter ASSIGNEE), is desirous of acquiring the entire right, title and interest in the same;


NOW, THEREFORE, in consideration of the sum of one dollar (\$1), the receipt of which is acknowledged, and other good and valuable consideration, I do sell, assign and transfer to ASSIGNEE the full and exclusive right to the said invention in the United States and in all foreign countries and the entire right, title and interest in and to any and all patents or similar legal protection which may be granted therefor in the United States and in all foreign countries from said application or any continuation, division, renewal, extension, substitute or reissue thereof or any legal equivalent thereof in a foreign country. I hereby authorize and request the Commissioner of Patents and Trademarks and any official of any foreign country whose duty it is to issue patents on applications as aforesaid, to issue said United States and foreign patents to ASSIGNEE, of the entire right, title and interest in and to same, for his sole use and behoof; and for the use and behoof of his legal representatives, to the full end of the term for which said patents may be granted, as fully and entirely as the same would have been held by us had this assignment and sale not been made.

SOLE OR FIRST INVENTOR	
Name	Leah Blasiak
Inventor's Signature	
Date	1/16/20

SECOND INVENTOR	
Name	William Nathan Cude
Inventor's Signature	
Date	

THIRD INVENTOR	
Name	Yaowei Kang
Inventor's Signature	
Date	

FOURTH INVENTOR	
Name	Kate Brandon Sutton
Inventor's Signature	
Date	1/7/2020

FIFTH INVENTOR	
Name	Timothy Liburn
Inventor's Signature	
Date	Jan. 17, 2020

SIXTH INVENTOR	
Name	Jonathan Pham
Inventor's Signature	
Date	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SUBSTITUTE STATEMENT IN LIEU OF AN OATH OR DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (35 U.S.C. 115(d) AND 37 CFR 1.64)

Title of Invention	BACILLUS ISOLATES AND USES THEREOF		
This statement is directed to:			
<input type="checkbox"/> The attached application,			
OR			
<input checked="" type="checkbox"/> United States application or PCT international application number <u>PCT/US2018/012152</u> filed on <u>January 3, 2018</u> .			
LEGAL NAME of inventor to whom this substitute statement applies:			
(E.g., Given Name (first and middle (if any)) and Family Name or Surname)			
Yaowei KANG			
Residence (except for a deceased or legally incapacitated inventor):			
City	State	Country	
Chapel Hill	NC	US	
Mailing Address (except for a deceased or legally incapacitated inventor):			
787 Covered Bridge Trail			
City	State	Zip	Country
Chapel Hill	NC	27517	US
I believe the above-named inventor or joint inventor to be the original inventor or an original joint inventor of a claimed invention in the application.			
The above-identified application was made or authorized to be made by me.			
I hereby acknowledge that any willful false statement made in this statement is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.			
Relationship to the inventor to whom this substitute statement applies:			
<input type="checkbox"/> Legal Representative (for deceased or legally incapacitated inventor only),			
<input checked="" type="checkbox"/> Assignee,			
<input type="checkbox"/> Person to whom the inventor is under an obligation to assign,			
<input type="checkbox"/> Person who otherwise shows a sufficient proprietary interest in the matter (petition under 37 CFR 1.46 is required), or			
<input type="checkbox"/> Joint Inventor.			

[Page 1 of 2]

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT
REEL: 052120 FRAME: 0911

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

SUBSTITUTE STATEMENT

Circumstances permitting execution of this substitute statement:

- Inventor is deceased,
- Inventor is under legal incapacity,
- Inventor cannot be found or reached after diligent effort, or
- Inventor has refused to execute the oath or declaration under 37 CFR 1.63.

If there are joint inventors, please check the appropriate box below:

- An application data sheet under 37 CFR 1.76 (PTO/AIA/14 or equivalent) naming the entire inventive entity has been or is currently submitted.

OR

- An application data sheet under 37 CFR 1.76 (PTO/AIA/14 or equivalent) has not been submitted. Thus, a Substitute Statement Supplemental Sheet (PTO/AIA/11 or equivalent) naming the entire inventive entity and providing inventor information is attached. See 37 CFR 1.64(b).

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

PERSON EXECUTING THIS SUBSTITUTE STATEMENT:Name: **Adam Rucker**

Date (Optional): 2020-01-17

Signature: **/Adam L. Rucker, Reg. No. 65933/****APPLICANT NAME AND TITLE OF PERSON EXECUTING THIS SUBSTITUTE STATEMENT:**

If the applicant is a juristic entity, list the applicant name and the title of the signer:

NOVOZYMES BIOAG A/S

Applicant Name:

Title of Person Executing
This Substitute Statement: **Senior Patent Attorney**

The signer, whose title is supplied above, is authorized to act on behalf of the applicant.

Residence of the signer (unless provided in an application data sheet, PTO/AIA/14 or equivalent):

City	State	Country
------	-------	---------

Mailing Address of the signer (unless provided in an application data sheet, PTO/AIA/14 or equivalent)

--	--	--	--

City	State	Zip	Country
------	-------	-----	---------

Note: Use an additional PTO/AIA/02 form for each inventor who is deceased, legally incapacitated, cannot be found or reached after diligent effort, or has refused to execute the oath or declaration under 37 CFR 1.63.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.